Regulatory & PolicySince the last major Ebola outbreak, substantial shifts have occurred in how governments, international agencies, and health systems approach disease containment, surveillance, and data use. This article delves into the lessons learned, the challenges persisting, and the changes defining our current response to Ebola.
Jonathan Blake·Jun 9, 2026
Regulatory & PolicyLast-minute revisions to Medicaid work requirements by CMS are raising alarm among stakeholders about the burden of additional paperwork and the risk of eligible participants losing coverage. This article analyzes the regulatory changes, examines arguments from policy experts and advocates, and explores the practical implications for beneficiaries and state agencies.
Jonathan Blake·Jun 8, 2026
Regulatory & PolicyOHRP’s diminished capacity raises red flags about oversight in human subject research, as ethics professionals depart amid growing complexity in biomedical and social science studies. This situation could have profound implications for research integrity, participant safety, and public trust in federally supported investigations. Current discussions focus on the underlying causes, the significance of a robust ethics framework, and possible strategies to rebuild this vital office.
Jonathan Blake·Jun 7, 2026
Biopharmaceutical IndustryBoehringer Ingelheim’s investigational drug Survodutide has demonstrated encouraging effects on liver fat reduction in obesity patients, though new data suggest its effect on overall weight loss may be less competitive compared to rival treatments. This nuanced outcome influences the drug’s potential role in obesity management strategies.
Jonathan Blake·Jun 7, 2026
Medical TechnologyMaternal health outcomes are under the microscope as health systems seek to improve safety. Technology offers promise, but its value hinges on early risk identification, fostering effective communication among caregivers, and catalyzing timely intervention, according to experts cited by MedCity News.
Jonathan Blake·Jun 7, 2026
Healthcare InvestmentHydrocephalus treatment is on the cusp of transformation with CereVasc’s minimally invasive eShunt system. The recent $85 million Series C funding round will support pivotal trials and regulatory submissions aimed at providing patients safer and more effective therapeutic options than conventional brain shunts.
Jonathan Blake·Jun 5, 2026
AI in Drug DiscoveryAlnylam Pharmaceuticals is moving decisively into AI-driven drug development through a partnership with Inceptive Nucleics. This collaboration promises to accelerate RNAi therapy creation by applying cutting-edge generative machine learning models.
Jonathan Blake·Jun 4, 2026
Healthcare InvestmentThis article explores how adopting a comprehensive identity strategy can improve data attribution accuracy, strengthen interoperability among healthcare entities, and ultimately support the effectiveness of value-based care initiatives.
Jonathan Blake·Jun 3, 2026
Biotech InnovationEmerging radiopharmaceuticals are increasingly becoming a focus in biotech, offering targeted therapeutic options that may improve the treatment landscape for complex diseases. Recent data indicate promise in the post-Pluvicto setting, underscoring the evolving opportunities in this field.
Jonathan Blake·Jun 2, 2026
Biotech InnovationCancer immunotherapy has revolutionized oncology care, yet high costs limit access in low-income settings. Recent clinical trial results showcase the promise of ultra-low dose strategies to extend survival in head and neck squamous cell carcinoma, opening new possibilities for global cancer treatment equity.
Jonathan Blake·May 31, 2026
AI in Drug DiscoveryThe application of artificial intelligence in healthcare continues to evolve, particularly in radiology, where AI technologies are revolutionizing image analysis. Beyond diagnostics, the introduction of a patient comprehension layer powered by AI has the potential to facilitate clearer communication of complex medical information.
Jonathan Blake·May 29, 2026
Biopharmaceutical IndustryNavigating job offers in a market favoring employers requires a nuanced approach. This article explores expert perspectives on negotiation strategies, frequent mistakes candidates make, and key advice for securing favorable employment terms in the biotech and pharmaceutical industries.
Jonathan Blake·May 28, 2026